GM2 gangliosidosis, 0 variant
News & Events
On this page
NCATS Co-Sponsored Conferences
American Society of Gene & Cell Therapy (ASGCT) 19th Annual Meeting, Wednesday, May 04, 2016 - Saturday, May 07, 2016
Location: Washington, DC
Description: Save the date and plan to head to Washington, DC on May 4-7, 2016, for the premiere gene and cell therapy conference in the world. Taking place at the Marriott Wardman Park Hotel, the ASGCT 19th Annual Meeting will feature ground breaking clinical trial results, cutting edge technology advancements, social networking events, and much more. Join over 1,900 of the worlds top gene and cell therapy professionals for four full days of educational offerings including plenary lectures given by Dr. David R. Liu and 2015 Japan Prize recipients, Dr. Alain Fischer, and Dr. Theodore Friedmann.
Gordon Research Conference and Gordon Research Seminar on Lysosomes and Endocytosis, Sunday, June 15, 2014 - Friday, June 20, 2014
Location: Proctor Academy, Andover, NH
Description: <p>The main goal of the Lysosomes and Endocytosis GRC is to foster the dissemination of current research results and the establishment of new research areas and new collaborations in the area of the cell biology of endocytosis, lysosomes, endosomes and related organelles. We hope that many of these new directions and collaborations will be directed toward the etiology, diagnosis and treatment of rare genetic diseases such as lysosomal storage disorders, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, Niemann Pick disease and tuberous sclerosis, among others.</p>
2013 Lysosomal Disease Gordon Research Conference and Gordon Research Seminar, Saturday, April 13, 2013 - Friday, April 19, 2013
Location: Lucca (Barga), Italy
Description: Conference goals: To support participation by junior investigators, including graduate students, postdoctoral fellows and new investigators who do not yet have individual and/or independent sources of funding to support their participation in such conferences. The goal is to have at least 40% of the participants at this meeting in this category and NIH funding will help ensure this level of participation. Indeed, at the 2011 inaugural meetings, fully one-third of the participants were graduate students/postdoctoral fellows/junior faculty. The selection of the meeting as host to a GRS will further enhance such participation by the next generation of leaders in the lysosomal disease research community. To further stimulate applications by investigators-in-training, a number of short talks will be chosen prior to the meeting based on abstract submissions, and moreover, a poster session, comprising nine short talks, will be chosen at the meeting on the basis of the posters which generate the most interest during the afternoon poster sessions.
WORLD Symposium 2010 (Lysosomal Disease Network's 6th Annual Research Meeting), Wednesday, February 10, 2010 - Friday, February 12, 2010
Location: Miami Hilton Downtown, Miami, Florida
Description: The specific aims of this meeting were to (1) emphasize the strategies for, and identify the obstacles to, moving from translational research to clinical trials; (2) coalesce members of the LD network into functional research collaborations and present to the LDN community progress on the specific projects that are part of the funded U54 RDCRN grant; (3) foster interdisciplinary collaboration with the overall goal of improving knowledge of basic discoveries and clinical manifestations of these diseases; (4) provide an educational forum for young investigators, clinicians, and researchers in the field; (5) identify and discuss the latest findings in the natural history of lysosomal diseases, diagnostic testing and screening, and treatment, with specific focus on (a) inflammatory components of lysosomal diseases and autophagy, especially in the central nervous system, (b) new treatments of the central nervous systems, and (c) ethics and efficacy in treating the presymptomatic or asymptomatic patient; and (6) identify areas requiring additional basic and clinical research and public policy and regulatory attention, such as ethics and economics, and factors that impact implementation of therapy, including newborn screening.